drugset / Trial / NCT07326995

Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

NCT07326995

Phase 2 Recruiting 60 enrolled Anhui Palo Alto Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhalation Aerosol in patients with bronchial asthma.

Timeline

Start
2025-02-24
Primary completion
2026-02
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PA9159 Small molecule 60 ug Oral
Subject PA9159 Small molecule 120 ug Oral
Subject PA9159 Small molecule 240 ug Oral

Indications